Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 6/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.38 |
| ▸ | CALCR | P30988 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31265393 | 0.90 | SLC15A2 (0.45) | SLC15A2FOLH1 | |
| SCHEMBL30632042 | 0.89 | BACE1 (0.40) | BACE1 | |
| SCHEMBL29381521 | 0.88 | BACE1 (0.40) | BACE1SLC15A2FOLH1 | |
| SCHEMBL29478145 | 0.88 | SLC15A2 (0.40) | BACE1SLC15A2FOLH1 | |
| SCHEMBL30974298 | 0.88 | FOLH1 (0.42) | BACE1SLC15A2FOLH1 | |
| SCHEMBL29557424 | 0.88 | SLC15A2 (0.43) | SLC15A2FOLH1 | |
| SCHEMBL30512656 | 0.87 | BACE1 (0.45) | BACE1 | |
| SCHEMBL21766761 | 0.87 | BACE1 (0.41) | BACE1SIRT2SIRT5 | |
| SCHEMBL29799996 | 0.86 | SLC15A2 (0.44) | SLC15A2 | |
| SCHEMBL30974127 | 0.86 | GLP1R (0.44) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | AVELAS ACQUISITION CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | FURIN 1272/4885BACE1 787/4885SLC15A2 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.